posted on 2024-10-10, 06:42authored byMegan L Gow, Hiba Jebeile, Eve T House, Shirley Alexander, Louise A Baur, Justin Brown, Clare E Collins, Chris T Cowell, Kaitlin Day, Sarah P Garnett, Alicia Grunseit, Mary-Kate Inkster, Cathy Kwok, Sarah Lang, Susan PaxtonSusan Paxton, Helen Truby, Krista A Varady, Natalie B Lister
The aim of this study was to determine the efficacy, safety and acceptability of a 4-week very-low-energy diet (VLED) program for adolescents with obesity. Adolescents (13-17 years) with obesity and ≥1 obesity-related complication were Fast Track to Health 52-week randomized controlled trial participants. Adolescents undertook a 4-week micronutrient-complete VLED (800 kcal/day), with weekly dietitian support. Anthropometric data were recorded at baseline and week-4 and side-effects at day 3-4, week-1, -2, -3 and -4. Adolescents completed an acceptability survey at week-4. A total of 134 adolescents (14.9 ± 1.2 years, 50% male) had a 5.5 ± 2.9 kg (p < 0.001) mean weight loss at week-4: 95% experienced ≥1 and 70% experienced ≥3 side-effects during the VLED program, especially during the first week. Hunger, fatigue, headache, irritability, loose stools, constipation and nausea were most common. Reporting more side-effects at day 3-4 correlated with greater weight loss at week-4 (r = -0.188, p = 0.03). Adolescents reported 'losing weight' (34%) and 'prescriptive structure' (28%) as the most positive aspects of VLED, while 'restrictive nature' (45%) and 'meal replacement taste' (20%) were least liked. A dietitian-monitored short-term VLED can be implemented safely and is acceptable for many adolescents seeking weight loss, despite frequent side-effects. Investigating predictors of acceptability and effectiveness could determine adolescents most suited to VLED programs.
Funding
This study was funded by the National Health and Medical Research Council (NHMRC) Project Grant (#1128317). MLG is supported by a NHMRC Peter Doherty Early Career Fellowship (#1158876). HJ is supported by an NHMRC Emerging Leadership (EL1) Investigator Grant (#2017139). LAB is in receipt of an NHMRC Leadership (L3) Investigator Grant (#2009035). CEC is supported by a NHMRC Leadership (L3) Investigator Grant (#2009340). KV receives funding from the National Institute of Health (R01DK128180; R01CA257807; R01DK119783). NBL is supported by an NHMRC Peter Doherty Early Career Fellowship (#114574).